Watchlist Price Alert

Daré Bioscience Inc. (DARE)

NASDAQ: DARE · Real-Time Price · USD

2.89

0.01 (0.35%)

At close: May 30, 2025, 3:57 PM

2.97

2.77%

After-hours: May 30, 2025, 04:04 PM EDT

0.35% (1D)

Bid	2.92
Market Cap	25.58M
Revenue (ttm)	9.8M
Net Income (ttm)	-1.68M
EPS (ttm)	-0.17
PE Ratio (ttm)	-17
Forward PE	-3.04
Analyst	Buy

Ask	3
Volume	11,941
Avg. Volume (20D)	18,035
Open	2.88
Previous Close	2.88
Day's Range	2.86 - 2.90
52-Week Range	2.67 - 6.24
Beta	1.20

About DARE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DARE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DARE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

9 months ago

+20%

Dare Bioscience shares are trading higher after th... Unlock content with Pro Subscription

9 months ago

+3.24%

Dare Bioscience shares are trading higher. The company reported Q2 financial results.

News

2 weeks ago · seekingalpha.com

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President ...

2 weeks ago · zacks.com

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago.

2 months ago · seekingalpha.com

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - Presiden...

2 months ago · zacks.com

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.72 per share a year ago.